March 30, 2018 – Boston-based recruiting firm Park Square Executive Search has recruited Dmitry Shashkov as president and CEO of Exogenesis Corp. He replaces company co-founder Richard Svrluga, who will continue to serve Exogenesis during the transition.
“We are very pleased to have Dmitry accept our offer to lead Exogenesis to its next level of growth and development,” said Mike Powell, chairman of the board of Exogenesis.
Mike O’Malley, board member and general partner at Inflection Point Ventures, said Dr. Shashkov is well qualified for the role. “Dmitry’s background and experience make him the ideal candidate for the top leadership position at Exogenesis,” he said.
Dr. Shashkov joins Exogenesis after several leadership roles in advanced materials industries. Most recently, he was president and CEO of H.C. Stark Fabricated Products, a global manufacturer of refractory metals serving aerospace, defense, medical, electronic and industrial markets. Dr. Shashkov also worked in business development and business management roles at Honeywell Specialty Materials, a $5 billion division of Honeywell. Before that, he worked at McKinsey & Company, managing projects in the chemical, pharmaceutical and telecommunication industries.
Headquartered in Billerica MA, Exogenesis is a private venture capital-backed company that has developed several accelerated particle-beam processing technologies to modify and control surfaces without applying a coating. The company’s proprietary Accelerated Neutral Atom Beam (ANAB) and Gas Cluster Ion Beam (GCIB) technologies are used for surface modification and control in a broad range of biomedical, optical and semiconductor applications.
The Search Consultants
Park Square works with leading biotechnology and high technology companies, major research universities and healthcare institutions, and venture capital and private equity firms, as well as their portfolio companies. The firm places board members, chief executive officers, C-suite executives as well as academic and physician leaders.
Select the Right Search Firm
Find out why CHROs and talent acquisition leaders turn to Hunt Scanlon’s Industry Media Center for the latest news and updates on executive search firms around the globe. Become a new member today.
The managing directors of the U.S. business of J. Robert Scott, a global search firm founded in 1986, spun out to form Park Square Executive Search in 2012. They include Jonathan Fortescue, Aaron Lapat, Erik Lundh and Bruce Rychlik.
Here is a look at some of the search work completed by Park Square over the past several months:
- The firm placed Erik T. Mitchell as university librarian at the University of California San Diego. Dr. Mitchell, who assumes his new role in April, currently serves as associate university librarian of Digital Initiatives and Collaborative Services and associate chief information officer at UC Berkeley.
- Threat Stack, providers of detection platforms for cloud, hybrid-cloud and on-premise environments, named Jonaki Egenolf as its first chief marketing officer and Chris Ford vice president of product. Park Square led both search assignments. Ms. Egenolf was previously VP of global marketing for Veracode, while Mr. Ford was chief product officer at Blue Cedar Networks.
Hunt Scanlon has developed a number of key branding opportunities for search firms on our mobile platform. From sponsored content to podcasts, videos and straight-up native brand advertising, you now can reach our expanding audience on the go.
- The search firm placed Robert Nagle as chief technology and product officer for Interactions, a provider of intelligent virtual assistants (IVAs) for enterprise customer care. Most recently, Mr. Nagle launched a start-up providing llarge-scaledata analytics for the enterprise.
- Park Square recruited Richard Wenstrup as chief medical officer of Oxford Immunotec Global, a high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. Most recently, Dr. Wenstrup served as CMO for Myriad Genetics.
- The firm placed Donald Haut as chief business officer of Histogenics Corp., a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space. Dr. Haut previously served as managing director of Haut Capital.
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; Stephen Sawicki, Managing Editor; and Andrew W. Mitchell, Managing Editor – Hunt Scanlon Media